Celcuity prices $60M common stock offering of 3.871M shares at $15.50

Celcuity Inc.

3,871,000 shares priced at $15.50 per share; gross proceeds $60.0M, net ~$56.2M.
Proceeds to fund working capital, R&D, and Phase 3 trial of gedatolisib for HR+/HER2- advanced breast cancer.
Investors include BVF Partners, Vivo Capital, Eventide Asset Management, Samlyn Capital, Driehaus Capital, Blue Owl Healthcare.
Offering closed May 31, 2024; existing cash plus proceeds expected to fund operations through at least H2 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.